Glucotrack (GCTK) EBITDA (2016 - 2020)
Historic EBITDA for Glucotrack (GCTK) over the last 7 years, with Q4 2020 value amounting to -$964000.0.
- Glucotrack's EBITDA fell 11482.41% to -$964000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was -$2.8 million, marking a year-over-year decrease of 17888.08%. This contributed to the annual value of -$7.1 million for FY2023, which is N/A changed from last year.
- Glucotrack's EBITDA amounted to -$964000.0 in Q4 2020, which was down 11482.41% from -$527000.0 recorded in Q3 2020.
- In the past 5 years, Glucotrack's EBITDA registered a high of $17.9 million during Q4 2017, and its lowest value of -$2.6 million during Q3 2017.
- Over the past 5 years, Glucotrack's median EBITDA value was -$1.0 million (recorded in 2019), while the average stood at $380433.4.
- Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 164790.68% in 2017, then crashed by 15731.09% in 2019.
- Over the past 5 years, Glucotrack's EBITDA (Quarter) stood at -$1.2 million in 2016, then soared by 1647.91% to $17.9 million in 2017, then plummeted by 107.37% to -$1.3 million in 2018, then skyrocketed by 592.99% to $6.5 million in 2019, then plummeted by 114.82% to -$964000.0 in 2020.
- Its EBITDA stands at -$964000.0 for Q4 2020, versus -$527000.0 for Q3 2020 and -$599000.0 for Q2 2020.